Facebook
X
LinkedIn
ForwardRadiopharmaceuticals
Radiopharmaceutical therapy has been a breakthrough technology and has a growing role in radiation oncology practices in both academic and community centers. For this session, we review currently FDA approved agents and clinical indications as well as briefly discuss upcoming agents/indications. We also review important considerations for starting a radiopharmaceutical therapy program and safety guidelines.
Target Audience
The meeting is designed to meet the interests of practicing radiation oncologists, radiation oncology residents, medical and clinical physicists, radiation therapists, radiation dosimetrists, nurses and all other health professionals involved in the field of radiation oncology.
Learning Objectives
Upon completion of this activity, participants should be able to do the following:
- Describe the basics of theranostics and radiopharmaceutical therapy.
- Identify current FDA approved indications and clinical data.
- Identify needs for implementing a new radiopharmaceutical therapy program.
Moderator
- Sue Yom, MD, MPH, FASTRO, University of California, San Francisco
Speaker
- Ravi Patel, MD, PhD, University of Pittsburgh Hillman Cancer Center
The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Available Credit
- 1.00 AMA PRA Category 1 Credit™
The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council for Continuing Medical Education for physicians. ASTRO designates this for a maximum of 1.00 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
- 1.00 Certificate of AttendanceThis activity was designated for 1.00 AMA PRA Category 1 Credit™.